https://doi.org/10.4081/itjm.2024.1758

Age- and dose-independent adverse effect of venlafaxine-extended release on blood pressure: a case series of 13 normotensive psychiatric outpatients

Vol. 18 No. 3 (2024)
Submitted: 17 June 2024
Accepted: 24 June 2024
Published: 10 July 2024
Blood pressure, patients, venlafaxine
Abstract Views: 5748
PDF: 390
HTML: 117
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Mohsen Khosravi
dr_khosravi2016@yahoo.com
https://orcid.org/0000-0003-2970-6309
Department of Psychiatry, School of Medicine, Zahedan University of Medical Sciences; Health Promotion Research Center, Zahedan University of Medical Sciences, Iran, Islamic Republic of.

Dear Editor, the first antidepressant medication of the serotonin-norepinephrine reuptake inhibitor class is venlafaxine (effexor), which is taken orally with a half-life of 5 hours; however, its effective and chief metabolite (i.e., O-desmethylvenlafaxine) owns a half-life of 11 hours. [...]

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

PlumX Metrics

PlumX Metrics  provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Montastruc JL, Rousseau V, de Canecaude C, et al. Role of serotonin and norepinephrine transporters in antidepressant-induced arterial hypertension: a pharmacoepidemiological-pharmacodynamic study. Eur J Clin Pharmacol 2020;76:1321-7. DOI: https://doi.org/10.1007/s00228-020-02913-0
O’Donnell JM, Bies RR, Williams AJ. Drug therapy of depression and anxiety disorders. In: Brunton LL, Knollman BC. (eds). Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, 14th ed. McGraw-Hill Education, New York; 2023.
Wathra R, Mulsant BH, Thomson L, et al. Hypertension and orthostatic hypotension with venlafaxine treatment in depressed older adults. J Psychopharmacol 2020;34:1112-8. DOI: https://doi.org/10.1177/0269881120944154
Kıvrak Y, Güvenç TS, Akbulut N, et al. Accelerated hypertension after venlafaxine usage. Case Rep Psychiatry 2014:2014:659715. DOI: https://doi.org/10.1155/2014/659715
Humbert X, Fedrizzi S, Chrétien B, et al. Hypertension induced by serotonin reuptake inhibitors: analysis of two pharmacovigilance databases. Fundam Clin Pharmacol 2019;33:296-302. DOI: https://doi.org/10.1111/fcp.12440

How to Cite

Khosravi, M. (2024). Age- and dose-independent adverse effect of venlafaxine-extended release on blood pressure: a case series of 13 normotensive psychiatric outpatients. Italian Journal of Medicine, 18(3). https://doi.org/10.4081/itjm.2024.1758
Copyright (c) 2024 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.